

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.usplo.gov

APPLICATION 1	٧٥.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/084,293	-	02/25/2002	Mark W. Leiby	68703/152	7984	
26646	75	90 03/19/2004		EXAMINER		
	KENYON & KENYON ONE BROADWAY				MICHENER, JENNIFER KOLB	
01.2 -11	NEW YORK, NY 10004			ART UNIT	PAPER NUMBER	
				1762		
				DATE MAILED: 03/19/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(a)					
, .		Applicant(s)					
Office Action Summary	10/084,293	LEIBY ET AL.					
· · · · · · · · · · · · · · · · · · ·	Examiner	Art Unit					
The MAN INC DATE of this	Jennifer K Michener	1762					
The MAILING DATE of this communication appe Period for Reply			SS				
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply of NO period for reply is specified above, the maximum statutory period with the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	6(a). In no event, however, may a reply be tin within the statutory minimum of thirty (30) day ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this commu D (35 U.S.C. § 133).	nication.				
Status		·					
1)⊠ Responsive to communication(s) filed on <u>25 Fe</u>	<u>bruary 2002</u> .						
2a) This action is <b>FINAL</b> . 2b) ☐ This	action is non-final.						
3)☐ Since this application is in condition for allowan	·_						
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4)⊠ Claim(s) <u>1-23</u> is/are pending in the application.							
4a) Of the above claim(s) <u>5-7,10 and 18-23</u> is/al	re withdrawn from consideration						
5) ☐ Claim(s) is/are allowed.	ward with the moon so the consideration.	•					
6)⊠ Claim(s) <u>1-4,8,9 and 11-17</u> is/are rejected.							
7) Claim(s) is/are objected to.							
8) Claim(s) are subject to restriction and/or	election requirement						
	oroston roquiloment.						
Application Papers							
9) The specification is objected to by the Examiner							
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction	on is required if the drawing(s) is obj	ected to. See 37 CFR 1.	121(d).				
11)☐ The oath or declaration is objected to by the Exa	aminer. Note the attached Office	Action or form PTO-1	52.				
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign p a) All b) Some * c) None of:	priority under 35 U.S.C. § 119(a)	-(d) or (f).					
<ul> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> </ul>							
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).							
	• • • • • • • • • • • • • • • • • • • •	d					
* See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s)							
1) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	te					
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 5/23/02&8/11/03.	5)  Notice of Informal Pa	atent Application (PTO-152)	1				
S. Patent and Trademark Office	- — — — — — — — — — — — — — — — — — — —						

Art Unit: 1762

#### **DETAILED ACTION**

### Election/Restrictions

 Applicant's election without traverse of Group I and the stent substrate is acknowledged.

### Information Disclosure Statement

2. The information disclosure statement filed 5/23/2002 fails to comply with 37 CFR 1.98(a)(2), which requires a legible copy of each U.S. and foreign patent; each publication or that portion which caused it to be listed; and all other information or that portion which caused it to be listed. It has been placed in the application file, but the information referred to therein has not been considered.

As noted on the copy of this IDS, Examiner has considered the U.S. references, but was unable to find copies of the non-patent literature documents in the application file. Submission (or re-submission) of these documents would be greatly appreciated and consideration thereof will be noted in the next office action.

## Claim Rejections - 35 USC § 112

3. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

\_ - -

Art Unit: 1762

4. Claims 1-4 and 8-9 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The word "isotropically" is unclear. The specification states that a cloud of turbulent coating is formed due to the ultrasonic nozzle and the evaporation of the solvent prior to impact, however it is unclear to Examiner how a turbulent cloud can create isotropic impact. Webster's and Hack's defines isotropic as exhibiting properties with the same values when measured along axes in all directions. If a turbulent, chaotic cloud encompasses a substrate, the properties would not appear to Examiner to have the same values in all directions. Also, it is not clear to what properties Applicant refers. Properties of impact could include droplet size, speed, direction, and force, among others.

## Claim Rejections - 35 USC § 102

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 6. Claims 11-13, 15-16 are rejected under 35 U.S.C. 102(b) as being anticipated by Hossainy et al. (6,153,252).

Hossainy et al. teach a process for coating a stent substrate with an organic compound in a containment system by spraying an organic (polymeric) compound in solvent

Art Unit: 1762

(liquid) via an ultrasonic nozzle to form micron-sized droplets, which impact on the substrate. Hossainy teaches subsequent drying, which removes the solvent (Example 6). Hossainy's containment system is used to slow evaporation and functions as Applicant's chamber. The pressure used by Hossainy is inherently controlled. Since the containment system is used to slow evaporation, the liquid is inherently volatile because evaporation occurs. Since the same type of SonoTek ultrasonic nozzle, droplet size, volatile liquid (col. 6, line 66), "cloud" coating formation, and substrate is used by Hossainy as by Applicant, the microdroplets formed by Hossainy must inherently impact "isotropically" on the surface of Hossainy's stent in the same manner of impact as Applicant's method.

7. Claims 1 and 8 are rejected under 35 U.S.C. 102(b) as being anticipated by Versteeg et al. (5,451,260).

Versteeg teaches using an ultrasonic nozzle liquid delivery system to form a thin film on a substrate. The substrate of Versteeg is placed in a vacuum chamber. A mixture of a volatile liquid with organic compound therein is prepared (col. 3, lines 24-27; col. 5, line 54). In the batch operation, a discreet amount of the coating mixture is metered into a storage line (col. 4, line 39). The chamber is evacuated by Versteeg (col. 3, lines 57-58). Versteeg supplies an inert gas to the chamber (col. 3, line 23). Versteeg controls the pressure in the chamber (col. 4, lines 2-3). The mixture of Versteeg is introduced into the chamber via an ultrasonic nozzle to form a cloud for coating the substrate.

Art Unit: 1762

While Versteeg does not teach that the cloud is formed of micro-droplets for isotropic impact, Examiner notes that Versteeg teaches a fine mist of very small droplets (col. 2, line 10). Since Versteeg teaches all method limitations of Applicant and uses the same Sono-Tek ultrasonic spray device, the droplet size and impact would inherently meet these limitations of Applicant.

Regarding the limitation for drying the thin film, Examiner notes that the pressure of Versteeg is controlled to preferably volatilize the liquid prior to impact. However, Applicant's instant specification teaches the use of pressure to control the rate of evaporation of the liquid with examples inclusive of applying a coating with droplets that are nearly dry at impact to achieve uniformity of thickness on the substrate (p. 6, line 10). Since Applicant's process conditions are stated to be adjusted to achieve a full range of values, up to the almost completely dry status of the droplets, the instant method approaches a completely dry vapor deposition state as taught by Versteeg. The difference between Applicant's almost completely dry embodiment is not patentably distinct from Versteeg's dry embodiment. Additionally, it is Examiner's position that there would inherently be some small amount of liquid present in the coating of Versteeg which would subsequently evaporate off and "dry" as required by Applicant's claim.

### Claim Rejections - 35 USC § 103

8. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

Art Unit: 1762

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 9. The factual inquiries set forth in *Graham* **v.** *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:
  - Determining the scope and contents of the prior art.
  - 2. Ascertaining the differences between the prior art and the claims at issue.
  - 3. Resolving the level of ordinary skill in the pertinent art.
  - 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
- 10. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).
- 11. Claims 1-4, 8, and 14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hossainy et al. in view of Versteeg et al.

Hossainy et al. teach that which is disclosed above regarding coating a medical device in a chamber with an organic compound solution in a cloud formation with a Sono-Tek ultrasonic coater and then drying the coating. Hossainy et al. teaches that control of

Art Unit: 1762

solvent evaporation is achieved by using a containment device, but fails to teach the mechanism and specifics of the use of such evaporation-control device.

Versteeg teaches that which is disclosed above regarding coating a substrate in a cloud of organic material formed in a pressure-controlled chamber and applied with a Sono-Tek ultrasonic coater using a metering, evacuating, and purging step as outlined above. Since Hossainy and Versteeg both coat substrates with organic materials using the same ultrasonic coaters in a chamber and Versteeg specifically teachs the use of metering, evacuating, purging, and pressure-controlling to control evaporation of the solvent as also desired by Hossainy, Versteeg would have reasonably suggested the use of metering, evacuating, and purging, in the method of Hossainy. It would have been obvious to one of ordinary skill in the art to use the metering, evacuating, etc. conditions of Versteeg in the method of Hossainy to provide reproducible, uniform coatings in the method of Hossainy.

Hossainy's stent includes drug layers which inhibit restenosis.

It would have been obvious to use Versteeg's inert gases to dry the coating of Hossainy.

12. Claim 9 is rejected under 35 U.S.C. 103(a) as being unpatentable over Hossainy in view of Versteeg as applied to claims 1, 3-4, and 8 above, and further in view of Tedechi.

Art Unit: 1762

Hossainy in view of Versteeg teach that which is disclosed above including a method of coating stents with polymer coatings with drugs incorporated therein, but fails to specifically teach that the polymer coating may be a derivatized silane.

Tedechi teaches coating stents with derivatized silane polymer with drugs incorporated therein to provide a thromboresistant, biocompatible coating.

Since Hossainy in view of Versteeg teach coating stents with polymers and Tedechi teaches a suitable polymer for coating stents, Tedechi would have reasonably suggested the use of derivatized silane as the polymer in Hossainy in view of Tedechi. It would have been obvious to one of ordinary skill in the art to use the teachings of Tedechi in the method of Hossainy in view of Versteeg to provide a biocompatible, / thromboresistant coating in the method of Hossainy in view of Versteeg.

### Conclusion

13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer K Michener whose telephone number is (571) 272-1424. The examiner can normally be reached on Monday through Thursday and alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shrive P. Beck can be reached on 571-272-1415. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 10/084,293 Page 9

Art Unit: 1762

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Jennifer Kolb Michener

Patent Examiner

Technology Center 1700

1x4 mls

March 11, 2004